Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial

Sándor, Péter; Clemente, Laura Di; Coppola, Gianluca; Saenger, U.; Fumal, Arnaud; Magis, Delphine; Seidel, Laurence; Agosti, R.; Schoenen, Jean

doi:10.1212/01.wnl.0000151975.03598.ed

Cited by 321 publications

(197 citation statements)

References 10 publications

Supporting

Mentioning

175

Contrasting

Unclassified

Order By: Relevance

“…13 The 50% responder rate for attack frequency (Ն50% reduction) was 47.6% for CoQ10 vs 14.3% for placebo ( p ϭ 0.02). The actual reduction in attack frequency was Ϫ1.9 Ϯ 1.9 for CoQ10 and 0.09 Ϯ 1.9 for placebo ( p ϭ 0.05).…”

Section: Co-q10 (Water-soluble Disbursable Form Of Co-q10)mentioning

confidence: 95%

Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED]

et al. 2012

View full text Add to dashboard Cite

Objective: To provide updated evidence-based recommendations for the preventive treatment of migraine headache. The clinical question addressed was: Are nonsteroidal anti-inflammatory drugs (NSAIDs) or other complementary treatments effective for migraine prevention? Methods:The authors analyzed published studies from June 1999 to May 2009 using a structured review process to classify the evidence relative to the efficacy of various medications for migraine prevention. Results:The author panel reviewed 284 abstracts, which ultimately yielded 49 Class I or Class II articles on migraine prevention; of these 49, 15 were classified as involving nontraditional therapies, NSAIDs, and other complementary therapies that are reviewed herein.Recommendations: Petasites (butterbur) is effective for migraine prevention and should be offered to patients with migraine to reduce the frequency and severity of migraine attacks (Level A). Fenoprofen, ibuprofen, ketoprofen, naproxen, naproxen sodium, MIG-99 (feverfew), magnesium, riboflavin, and subcutaneous histamine are probably effective for migraine prevention (Level B). Treatments considered possibly effective are cyproheptadine, Co-Q10, estrogen, mefenamic acid, and flurbiprofen (Level C). Data are conflicting or inadequate to support or refute use of aspirin, indomethacin, omega-3, or hyperbaric oxygen for migraine prevention. Montelukast is established as probably ineffective for migraine prevention (Level B). Epidemiologic studies suggest approximately 38% of migraineurs need preventive therapy, but only 3%-13% currently use it.1 In 2000, the American Academy of Neurology (AAN) published guidelines for migraine prevention.2,3 Since then, new clinical studies have been published on the efficacy and safety of migraine preventive therapies. This guideline seeks to assess this new evidence to answer the following clinical question: For patients with migraine, which anti-inflammatory or complementary treatments are effective for prevention, as measured by reduced migraine attack frequency, reduced number of migraine days, or reduced attack severity? This article addresses the efficacy and safety of histamines/antihistamines; nonsteroidal anti-inflammatory drugs (NSAIDs) and analgesics; and several herbal, vitamin, and mineral preparations, whereas a companion article addresses standard pharmacologic treatments for migraine prevention.

show abstract

Section: Co-q10 (Water-soluble Disbursable Form Of Co-q10)mentioning

confidence: 95%

Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED]

et al. 2012

View full text Add to dashboard Cite

show abstract

“…CoQ10 has been suggested for treatment of a variety of diseases including heart failure [193] migraine [194], hypertension [195] and neurodegenerative diseases [196]. Although CoQ10 is considered a safe drug [197], additional studies are still required to prove its clinical usefulness [196].…”

Section: Coenzyme Q10mentioning

confidence: 99%

Clinical and pharmacological aspects of bath salt use: A review of the literature and case reports

Miotto¹,

Striebel²,

Cho

et al. 2013

Drug and Alcohol Dependence

121

View full text Add to dashboard Cite

Abstract:Reactive oxygen species (ROS) are widely believed to cause or aggravate several human pathologies such as neurodegenerative diseases, cancer, stroke and many other ailments. Antioxidants are assumed to counteract the harmful effects of ROS and therefore prevent or treat oxidative stress-related diseases. In this report, recent human studies exploring the efficiency of antioxidants in prevention and treatment of various diseases are reviewed. Few antioxidants including edaravone (for ischemic stroke in Japan), Nacetylcysteine (for acetaminophen toxicity), alfa-lipoic acid (for diabetic neuropathy) and some flavonoids (polyphenolic compounds present in dietary plants), such as micronized purified flavonoid fraction (diosmin and hesperidin) and oxerutins (for chronic venous insufficiency) as well as baicalein and catechins (for osteoarthritis) have found accepted clinical use. However, despite much enthusiasm in the 1980s and 1990s, many well-known agents such as antioxidant vitamins and also more recently developed compounds such as nitrones have not successfully passed the scrutiny of clinical trials for prevention and treatment of various diseases. This has given rise to a pessimistic view of antioxidant therapy, however, the evidence from human epidemiological studies about the beneficial effects of dietary antioxidants and preclinical in vitro and animal data are compelling. We have probably wasted too much time on agents like antioxidant vitamins instead of focusing on more disease specific, target-directed, highly bioavailable antioxidants. We here discuss possible reasons for the lack of success in some clinical trials and seek to provide some suggestions to be considered if antioxidant therapy is to succeed as an effective therapeutic strategy.

show abstract

“…ATP was found to be reduced in the occipital lobe of MwoA patients, however, ATP remains to be measured in MwA patients. Additional evidence supporting a disturbed energy metabolism in migraine, comes from pharmacological studies showing the effects of metabolic enhancers, such as riboflavin and coenzyme Q10 (both with a well defined role in mitochondrial membrane generation of ATP), in migraine prophylaxis (65)(66)(67)(68). It is worthy of note that the therapeutic response to riboflavin was associated with specific mitochondrial DNA haplogroups (69).…”

Section: Functional Paradigmmentioning

confidence: 99%

Magnetic resonance spectroscopy in migraine: What have we learned so far?

2012

View full text Add to dashboard Cite

Objective: To summarize and evaluate proton (1H) and phosphorus (31P) magnetic resonance spectroscopy (MRS) findings in migraine. Methods: A thorough review of 1H and/or 31P-MRS studies in any form of migraine published up to September 2011. Results: Some findings were consistent in all studies, such as a lack of ictal/interictal brain pH change and a disturbed energy metabolism, the latter of which is reflected in a drop in phosphocreatine content, both in the resting brain and in muscle following exercise. In a recent interictal study ATP was found to be significantly decreased in the occipital lobe of migraine with aura patients, reinforcing the concept of a mitochondrial component to the migraine threshold, at least in a subgroup of patients. In several studies a correlation between the extent of the energy disturbance and the clinical phenotype severity was apparent. Less consistent but still congruent with a disturbed energy metabolism is an observed lactate increase in the occipital cortex of several migraine subtypes (MwA, migraine with prolonged aura). No increases in brain glutamate levels were found. Conclusion: The combined abnormalities found in MRS studies imply a mitochondrial component in migraine neurobiology. This could be due to a primary mitochondrial dysfunction or be secondary to, for example, alterations in brain excitability. The extent of variation in the data can be attributed to both the variable clinical inclusion criteria used and the variation in applied methodology. Therefore it is necessary to continue to optimize MRS methodology to gain further insights, especially concerning lactate and glutamate.

show abstract

Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial

Cited by 321 publications

References 10 publications

Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED]

Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED]

Clinical and pharmacological aspects of bath salt use: A review of the literature and case reports

Magnetic resonance spectroscopy in migraine: What have we learned so far?

Contact Info

Product

Resources

About